Breaking News English

Paragraph 1

The next  approvalaverageexecutivegenerationpharmaceuticalpotentiallytrialsurgencyversionwidely of weight-loss drugs could be launched next year, and they could be game-changing. The treatment, being dubbed "Ozempic 2.0," is a pill  approvalaverageexecutivegenerationpharmaceuticalpotentiallytrialsurgencyversionwidely of the already  approvalaverageexecutivegenerationpharmaceuticalpotentiallytrialsurgencyversionwidely-used Ozempic. Novo Nordisk, the  approvalaverageexecutivegenerationpharmaceuticalpotentiallytrialsurgencyversionwidely company developing the new tablet form, said its initial clinical  approvalaverageexecutivegenerationpharmaceuticalpotentiallytrialsurgencyversionwidely revealed that Ozempic 2.0 "lowered weight by an  approvalaverageexecutivegenerationpharmaceuticalpotentiallytrialsurgencyversionwidely of 10.5 per cent". Rival company Eli Lilly is also working on a pill. Its  approvalaverageexecutivegenerationpharmaceuticalpotentiallytrialsurgencyversionwidely vice president, Kenneth Custer, said: "We are moving with  approvalaverageexecutivegenerationpharmaceuticalpotentiallytrialsurgencyversionwidely toward global regulatory submissions to  approvalaverageexecutivegenerationpharmaceuticalpotentiallytrialsurgencyversionwidely meet the needs of patients." The drugs are currently awaiting  approvalaverageexecutivegenerationpharmaceuticalpotentiallytrialsurgencyversionwidely from the Food and Drug Administration (FDA) in the USA.